急速成長的印度臨床實驗市場 是由出版商RNCOS E-Services Pvt. Ltd.在2011年08月所出版的。
這份英文市場調查報告書包含145 Pages 價格從美金1000起跳。
印度有10億以上的人口與各種危及生命的疾病，但這對全世界的醫療相關人員來說卻是研究與臨床實驗實施的機會。因此，印度成為全球最富有魅力的臨床實驗市場之一，這幾年該國的臨床實驗數量急速增加。
本報告提供印度的臨床實驗市場最新趨勢的相關調查，臨床實驗數量的變動，促進成長要素，人口規模和患者的提供，基本設備·人材的情形，成本分析，法規環境，再加上主要企業簡介，彙整以上種種資訊，為您概述為以下內容。
第1章 分析師的見解
第2章 調查方法
第3章 臨床實驗市場概要
- 臨床實驗市場
- 各類型臨床實驗
- 臨床實驗實施數量
- 各州臨床實驗
第4章 促進成長要素和新興趨勢
- 臨床實驗實施時的成本競爭力
- 臨床實驗迅速完成
- 政府的輔助
- 臨床實驗資料管理:對時間的要求
- 醫藥品的外包市場
- 病理學和診斷市場
第5章 規模及患者的提供
第6章 基礎設施及專門知識
第7章 商務外包模式
第8章 臨床實驗實施次序
第9章 相關法規
第10章 產業的障礙與警訊
第11章 臨床實驗成本分析
第12章 競爭環境
- 概要
- 競爭環境
- Veeda Clinical Research
- SIRO Clinpharm Private Limited
- Sipra Labs Limited
- Clinic International
- Clinigene International
- Quintiles India
- Synchron Research Services
- Max Neeman International
- DiagoSearch Life Sciences
- Vimta Lambs
- Lambda Therapeutic Reseaerch
- Ecron Acunova
圖表一覽
Abstract
India has billion plus population and a home for various life threatening
diseases. These factors provide an opportunity for global medical
practitioners and healthcare providers to consider India as an effective
destination for research and clinical studies. India has registered fast
growth in the number of clinical trials over the past few years, reflecting
that the country has become one of the most attractive destinations for
medical research.
According to our new research report, “Booming Clinical Trials Market in
India”, the number of clinical studies by domestic and global players
has sharply risen. The M&A activities, service agreements, and strategic
collaboration have increased over the last four years. The majority of the
deals in the contract research organizations market focused on establishing
strategic alliances with other contract research organizations, technology
providers, and pharmaceutical and biotech companies. In addition, on the back
of favorable government support and effective regulatory mechanism provided by
the ICMR and CDSCO, healthcare providers find it worthwhile to locate their
trials in India. Besides, availability of skilled manpower and good medical
infrastructure will augment the number of clinical trials from 1300 in 2009 to
more than 1900 by 2013.
We have analyzed the Indian clinical trial market with emphasis on current
market trends and future outlook. Our report has found that with the rising
participation of private players and improvement in the number of medical
professionals, new avenues of research will be developed in the country. All
these factors will facilitate market development and boost market growth in
future. A large number of patients for clinical trials are expected to
strengthen the market even more.
Our study indicates that, India, over the last decade, has developed
significant capabilities in clinical trials, along with certain capabilities
in project management and data management. India is able to provide
significant cost savings of 50-60% for clinical trials. With discovery
research occupying close to one-third of the R&D expenditure for the western
pharmaceutical industry, outsourcing to low-cost countries is logical. As the
financial and regulatory pressure grows on the US and European pharmaceutical
industry, it is expected to further propel the growth in the Indian clinical
trial market.
Our report is an outcome of extensive research and prudent analysis of the
Indian clinical trial market. The report covers all the necessary segments of
the sector, providing reliable and latest data of the industry. The report
also presents future outlook of different areas. Moreover, the description of
key players and their recent activities have been covered in the report.
Table of Contents
1. Analyst View
2. Research Methodology
3. Clinical Trials Market Overview
- 3.1. Clinical Trials Market
- 3.2. Clinical Trials by Type
- 3.3. Number of Clinical Trials
- 3.4. State-wise Trials
4. Growth Facilitators and Emerging Trends
- 4.1. Cost Competitiveness in Conducting Clinical Trials
- 4.2. Faster Completion of Clinical Trials
- 4.3. Government Support
- 4.4. Clinical Data Management: Demand of the Hour
- 4.5. Pharma Outsourcing Market
- 4.6. Pathology and Diagnostic Market
5. Size and Patient Pool Availability
- 5.1. Demographics Profile
- 5.2. Disease Profile
- 5.3. Patient Availability and Recruitment
6. Infrastructure and Expertise
7. Business Outsourcing Models Followed by Players
8. Procedure for Conducting Clinical Trials
9. Regulatory Environment
10. Industry Bottlenecks and Precautions
11. Cost Analysis for Clinical Trials
- 11.1. Total Budget Cost
- 11.2. Cost Comparison with US
- 11.3. Cost Analysis by Phases
- 11.3.1. Phase I (Cost of Utility and Staff)
- 11.3.2. Phase II (Cost of Utility and Staff)
- 11.3.3. Phase III (Cost of Utility and Staff)
- 11.3.4. Phase IV (Cost of Utility and Staff)
12. Competitive Landscape
- 12.1. Overview
- 12.2. Competitive Landscape
- 12.2.1. Veeda Clinical Research
- 12.2.2. SIRO Clinpharm Private Limited
- 12.2.3. Sipra Labs Limited
- 12.2.4. Clintrac International
- 12.2.5. Clinigene International
- 12.2.6. Quintiles India
- 12.2.7. Synchron Research Services
- 12.2.8. Max Neeman International
- 12.2.9. DiagnoSearch Life Sciences
- 12.2.10. Vimta Labs
- 12.2.11. Lambda Therapeutic Research
- 12.2.12. Ecron Acunova
List of Figures:
- Figure 3-1: Clinical Research Outsourcing Market (Million US$), 2009-2015
- Figure 3-2: Clinical Trials by Phase (%)
- Figure 3-3: Clinical Trials by Therapy (%)
- Figure 3-4: Clinical Trials by Funding (%)
- Figure 3-5: Number of Global and Local Trials Permitted (2007-2010)
- Figure 3-6: Number of Clinical Trials (2007 & 2009)
- Figure 4-1: Average Annual Cost for Conducting Clinical Trials in
Comparison to US
- Figure 4-2: Investigator Cost per Visit in Comparison to US, UK and
Singapore
- Figure 4-3: Numbers of Clinical Trials Completed on Time in Comparison to
UK, US and Germany
- Figure 4-4: Time Taken for Conducting Clinical Trials by Phase in
Comparison to US (Months)
- Figure 4-5: Pharma Outsourcing Market (Billion US$), 2009-2013
- Figure 4-6: Pharma Outsourcing Market by Segment (%), 2008
- Figure 4-7: IVD Market (Million US$), 2009 & 2012
- Figure 5-1: Population (Million), 2009-2013
- Figure 5-2: Population Breakup by Age Group (%), 2009-2013
- Figure 5-3: New and Total Number of Cancer Patients (‘000)
- Figure 5-4: Number of Hypertension Patients (Million), 2009 & 2025
- Figure 5-5: Number of Coronary Heart Disease Patients (Million), 2010 &
2015
- Figure 5-6: Recruitment Time for Patients Participating in Clinical Trials
in Comparison to US (Days)
- Figure 5-7: Number of Patient per Site in Comparison to US
- Figure 6-1: Annual Supply of Science Graduates and Postgraduates
(‘000)
- Figure 6-2: Number of Graduates and Postgraduates (Million), 2004
- Figure 6-3: Share of Science Doctorates in Total Doctorates (2004)
- Figure 6-4: Number of Doctors in Comparison to US and Germany (per
‘000 Population), 2009
- Figure 6-5: Demand-Supply Gap in Clinical Research Professionals (Number),
2010
- Figure 6-6: Number of GCP Trained Investigators (2002 & 2005)
- Figure 6-7: Number of GCP Trained Investigators in Comparison to US
- Figure 6-8: Number of Hospital Beds (‘000), 2009-2013
- Figure 6-9: Hospital Beds Density of Key Countries (per ‘000
Population), 2010
- Figure 6-10: Number of Industry Sponsored Phase II-III Clinical Trial
Sites of Key Countries
- Figure 11-1: Average Cost per Patient for Conducting Clinical Trials in
Comparison to UK, US and Germany (US$)
- Figure 11-2: Average Cost per Patient for Conducting Phase I Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-3: Average Cost per Patient for Conducting Phase II Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-4: Annual Cost of Office Space for Conducting Phase II Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-5: Average Cost per Patient for Conducting Phase III Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-6: Annual Cost of Office Space for Conducting Phase III Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-7: Average Cost per Patient for Conducting Phase IV Clinical
Trials in Comparison to UK, US and Germany (US$)
- Figure 11-8: Annual Cost of Office Space for Conducting Phase IV Clinical
Trials in Comparison to UK, US and Germany (US$)
List of Tables:
- Table 3-1: Details of State-wise Clinical Trials (January-July 2011)
- Table 4-1: Features of Clinical Trials in Comparison to US
- Table 5-1: Number of Deaths due to Leading Causes in Middle Income
Countries (Million)
- Table 5-2: Number of Diabetic Patients in Age Group 20-79 (‘000),
2010
- Table 5-3: Forecast for Number of Diabetic Patients in Age Group 20-79
(‘000), 2030
- Table 5-4: New Cancers Incidences (per ‘00,000 Females), 2005
- Table 5-5: New Cancers Incidences (per ‘00,000 Males), 2005
- Table 5-6: Obesity Statistics (2009)
- Table 6-1: Structure of Medical Education
- Table 6-2: Number of GLA Approved Facilities by Type
- Table 9-1: Regulatory Bodies Involved in Pharmaceutical Regulation
- Table 9-2: Regulatory Timelines for Conducting Clinical Trials
- Table 11-1: Average Cost of Clinical Research in Comparison to US by Phase
(Million US$)
- Table 11-2: Calculation of Clinical Trials Costs Savings in Comparison to
US
- Table 11-3: Annual Cost of Staff for Conducting Phase I Clinical Trials in
Comparison to UK, US and Germany (US$)
- Table 11-4: Annual Cost of Utility for Conducting Phase I Clinical Trials
in Comparison to UK, US and Germany (US$)
- Table 11-5: Annual Cost of Staff for Conducting Phase II Clinical Trials
in Comparison to UK, US and Germany (US$)
- Table 11-6: Annual Cost of Utility for Conducting Phase II Clinical Trials
in Comparison to UK, US and Germany (US$)
- Table 11-7: Annual Cost of Staff for Conducting Phase III Clinical Trials
in Comparison to UK, US and Germany (US$)
- Table 11-8: Annual Cost of Utility for Conducting Phase III Clinical
Trials in Comparison to UK, US and Germany (US$)
- Table 11-9: Annual Cost of Staff for Conducting Phase IV Clinical Trials
in Comparison to UK, US and Germany (US$)
- Table 11-10: Annual Cost of Utility for Conducting Phase IV Clinical
Trials in Comparison to UK, US and Germany (US$)
|
